MicroRNA-124-3p Modulates Alpha-Synuclein Expression Levels in a Paraquat-Induced in vivo Model for Parkinson’s Disease
Neurochemical Research · 2024
DOI: 10.1007/s11064-024-04130-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurochemical Research, 2024. Verfasst von Marta Esteves und 5 weiteren Autor:innen. Beteiligte Einrichtung: CICS-UBI Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal. Hauptthemen laut MEDLINE: MicroRNAs, alpha-Synuclein, Paraquat. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidade da Beira Interior.
Abstract (Originalsprache)
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease and the most common movement disorder. Although PD etiology is not fully understood, alpha (α)-synuclein is a key protein involved in PD pathology. MicroRNAs (miRNA), small gene regulatory RNAs that control gene expression, have been identified as biomarkers and potential therapeutic targets for brain diseases, including PD. In particular, miR-124 is downregulated in the plasma and brain samples of PD patients. Recently we showed that the brain delivery of miR-124 counteracts 6-hydroxydopamine-induced motor deficits. However, its role in α-synuclein pathology has never been addressed. Here we used paraquat (PQ)-induced rat PD model to evaluate the role of miR-124-3p in α-synuclein accumulation and dopaminergic neuroprotection. Our results showed that an intranigral administration of miR-124-3p reduced the expression and aggregation of α-synuclein in the substantia nigra (SN) of rats exposed to PQ. NADPH oxidases (NOX), responsible for reactive oxygen species generation, have been considered major players in the development of α-synuclein pathology. Accordingly, miR-124-3p decreased protein expression levels of NOX1 and its activator, small GTPase Rac1, in the SN of PQ-lesioned rats. Moreover, miR-124-3p was able to counteract the reduced levels of pituitary homeobox 3 (PITX3), a protein required for the dopaminergic phenotype, induced by PQ in the SN. This is the first study showing that miR-124-3p decreases PQ-induced α-synuclein levels and the associated NOX1/Rac1 signaling pathway, and impacts PITX3 protein levels, supporting the potential of miR-124-3p as a disease-modifying agent for PD and related α-synucleinopathies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CICS-UBI Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal.
- NeuroSov, UBImedical, University of Beira Interior, Covilhã, Portugal.
- CEDOC, NOVA Medical School, Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Lisboa, Portugal.
- CICS-UBI Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal. libernardino@fcsaude.ubi.pt.
- Brain Repair Group, CICS-UBI Health Sciences Research Centre, University of Beira Interior, Av. Infante D. Henrique, Covilhã, 6200-506, Portugal. libernardino@fcsaude.ubi.pt.
Förderung
- Universidade da Beira Interior
Zitieren
APA
Esteves, M., Cristóvão, A. C., Vale, A., Machado-Pereira, M., Ferreira, R., & Bernardino, L. (2024). MicroRNA-124-3p Modulates Alpha-Synuclein Expression Levels in a Paraquat-Induced in vivo Model for Parkinson’s Disease. Neurochemical Research. https://doi.org/10.1007/s11064-024-04130-y
Vancouver
Esteves M, Cristóvão AC, Vale A, Machado-Pereira M, Ferreira R, Bernardino L. MicroRNA-124-3p Modulates Alpha-Synuclein Expression Levels in a Paraquat-Induced in vivo Model for Parkinson’s Disease. Neurochemical Research. 2024. doi:10.1007/s11064-024-04130-y
BibTeX
@article{Esteves2024,
author = {Esteves, Marta and Cristóvão, Ana Clara and Vale, Ana and Machado-Pereira, Marta and Ferreira, Raquel and Bernardino, Liliana},
title = {MicroRNA-124-3p Modulates Alpha-Synuclein Expression Levels in a Paraquat-Induced in vivo Model for Parkinson’s Disease},
journal = {Neurochemical Research},
year = {2024},
doi = {10.1007/s11064-024-04130-y}
}
EUVIMED